deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01527045

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation

Sponsor: Fred Hutchinson Cancer Center

Conditions Aggressive Non-Hodgkin Lymphoma Blasts Under 5 Percent of Bone Marrow Nucleated Cells Chronic Lymphocytic Leukemia Loss of Chromosome 17p Myelodysplastic/Myeloproliferative Neoplasm Non-Hodgkin Lymphoma Prolymphocytic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Aggressive Adult Non-Hodgkin Lymphoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Diffuse Large B-Cell Lymphoma Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma Recurrent Small Lymphocytic Lymphoma Waldenstrom Macroglobulinemia
Interventions Atorvastatin Calcium Cyclosporine Fludarabine Phosphate Laboratory Biomarker Analysis Mycophenolate Mofetil Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Peripheral Blood Stem Cell Transplantation Total-Body Irradiation
Updated 15 times since 2017 Last updated: Dec 26, 2019 Started: Sep 25, 2012 Primary completion: Oct 31, 2018 Completion: Apr 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Aggressive Non-Hodgkin Lymphoma and Blasts Under 5 Percent of Bone Marrow Nucleated Cells and is currently completed. Fred Hutchinson Cancer Center leads this study, which shows 15 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Mar 2018 · 5 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Dec 2019 · 7 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. May 2022 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 10 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  4. May 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Dec 2018 — May 2019 [monthly]

    Recruiting PHASE2

  6. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  7. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  8. Oct 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  9. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations